BCR-ABL-negative chronic myeloid leukemia

被引：4
作者：
Burgstaller S. [1 ]
Reiter A. [1 ]
Cross N.C.P. [1 ]
机构：
[1] Wessex Regional Genetics Laboratory, University of Southampton, Salisbury NHS Foundation Trust
来源：
Current Hematologic Malignancy Reports | 2007年 / 2卷 / 2期
关键词：
Imatinib; Chronic Myeloid Leukemia; Polycythemia Vera; Myeloproliferative Disorder; Systemic Mastocytosis;
D O I：
10.1007/s11899-007-0011-5
中图分类号：
学科分类号：
摘要：
Constitutive activation of protein tyrosine kinases plays a central role in the pathogenesis of myeloproliferative disorders, including BCR-ABL-negative chronic myeloid leukemia. Current research is focused on elucidating the full spectrum of causative mutations in this rare, heterogeneous disease. Activated tyrosine kinases are excellent targets for signal transduction therapy, and an accurate diagnosis including morphology, karyotyping, and molecular genetics will become increasingly important to direct individualized treatment. In addition, new molecular findings need to be incorporated into disease classification systems. Copyright © 2007 by Current Medicine Group LLC.
引用
收藏
页码：75 / 82
页数：7
相关论文
共 75 条
[1]  
Vardiman J.W., Harris N.L., Brunnmg R.D., The World Health Organization (WHO) classification of the myeloid neoplasms, Blood, 100, pp. 2292-2302, (2002)
[2]  
Chase A., Huntly B.J., Cross N.C.P., Cytogenetics of chronic myeloid leukaemia, Best Bract Res Clin Haematol, 14, pp. 553-571, (2001)
[3]  
Onida F., Ball G., Kantarjian H.M., Et al., Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia, Cancer, 95, pp. 1673-1684, (2002)
[4]  
Steer F.J., Cross N.C.P., Myeloproliferative disorders with translocations of chromosome 5q31-35: Role of the platelet-derived growth factor receptor-β, Acta Haematol, 107, pp. 113-122, (2002)
[5]  
Baxter E.J., Hochhaus A., Bolufer P., Et al., The t(4
[6]  
22)(q12
[7]  
q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA, Hum Mol Genet, 11, pp. 1391-1397, (2002)
[8]  
Trempat P., Villalva C., Laurent G., Et al., Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor alpha receptor: A new clinical target for STI571/Glivec, Oncogene, 22, pp. 5702-5706, (2003)
[9]  
Cools J., DeAngelo D.J., Gotlib J., Et al., A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome, N Engl J Med, 348, pp. 1201-1214, (2003)
[10]  
Griffin J.H., Leung J., Bruner R.J., Et al., Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome, Proc Natl Acad Sci U S A, 100, pp. 7830-7835, (2003)
12345678